Reviv3 Procare Delivers Record Second Quarter Fiscal 2023 Revenue and Earnings
In the second quarter of 2023, Reviv3 Procare Company (RVIV) reported revenues of $6.7 million, a remarkable 1,264% increase year-over-year, driven by its hearing protection and enhancement business acquisition. Gross profit surged to $5.0 million with a margin of 75%. The company achieved a net income of $987,944 before tax provisions, a significant rise from $28,201 in the prior year. Operating cash flow also improved, generating $2.2 million in the first half of 2023. Management expects future product launches and strategic partnerships to bolster growth.
- Record revenues of $6.7 million, up 1,264% year-over-year.
- Gross profit increased to $5.0 million with a margin of 75%.
- Net income of $987,944 compared to $28,201 in the prior year quarter.
- Net cash generated from operating activities of $2.2 million for the first six months.
- Cost of sales increased to $1.69 million, leading to a slight decrease in gross margin from 77% to 75% year-over-year.
- Record second quarter 2023 revenues of
$6.7 million , up 1,264% year-over-year. - Gross profit increased to
$5.0 million compared to$0.4 million for the prior year quarter. - Net cash generated from operating activities of
$2.2 million with a net increase in cash of over$3.6 million for the first six months of 2023. - Net income before provisions for income tax of
$987,944 compared to$28,201 in the prior year quarter.
LOS ANGELES, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Reviv3 Procare Company (OTCQB: RVIV), an emerging global e-commerce brand for hair care products and hearing protection and enhancement products, today announced its financial and operational results for second quarter of fiscal year 2023.
Second Quarter Fiscal 2023 Financial Summary
The company reported revenues of
Cost of sales for the second quarter of 2023 increased to
Gross profit for the second quarter of 2023 increased to a record
Net cash flows provided by operating activities for the six months ended November 30, 2022 was
As a result of the above, we reported a net income of
Management Commentary
“We delivered solid results with record second quarter revenues of
“These results reflect the strength of our hearing protection and enhancement products sold under the AXIL brand across our retail network and digital marketing channels. Despite the challenging economic conditions and ongoing supply chain disruptions our team continues to execute our marketing and operational initiatives. Looking ahead, we expect to introduce a number of impactful new products and strategic partnerships to further enhance our ability to expand market share and generate free cash flow in 2023 and beyond,” Concluded Toghraie.
About Reviv3 Procare Company
Reviv3 Procare Company (OTCQB: RVIV) is an emerging global e-commerce consumer products company. The Company is a direct-to-consumer marketer of premium hair and skincare products under its in-house Reviv3 Procare brand and hearing enhancement and protection products, including ear plugs, earmuffs and ear buds, under the brand AXIL - selling products in the United States, Canada, the European Union and throughout Asia. To learn more, please visit the Company's website at www.reviv3.com and, for the AXIL brand, visit www.goaxil.com.
Forward-Looking Statements
This press release contains a number of forward-looking statements within the meaning of the federal securities laws. The use of words such as "anticipates," "expects," "intends," "plans," “will,” “may,” “should,” “could,” “would,” “guidance,” “outlook,” "confident that" and "believes," among others, generally identify forward-looking statements.
These forward-looking statements are based on currently available information, and management's beliefs, projections, and current expectations, and are subject to a number of significant risks and uncertainties, many of which are beyond management’s control and may cause Reviv3’s results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, among other things: (i) Reviv3's ability to grow net sales as anticipated, generate free cash flow, and perform in accordance with guidance; (ii) our ability to generate sufficient revenue to support Reviv3’s operations and to raise additional funds or obtain other forms of financing as needed on acceptable terms, or at all; (iii) potential difficulties or delays Reviv3 may experience in implementing its cost savings and efficiency initiatives, including integrating the AXIL brand; (iv) Reviv3's ability to compete effectively with other hair and skincare companies and hearing enhancement and protection companies; (v) Reviv3’s ability to successfully execute its marketing, operational and strategic initiatives, including entering into strategic partnerships or other collaborations, and to expand its market share; (vi) Reviv3’s ability to successfully introduce, and achieve market acceptance of, new products; (vii) the concentration of Reviv3's customers, potentially increasing the negative impact to Reviv3 by changing purchasing or selling patterns; (viii) changes in laws or regulations in the United States and/or in other major markets, such as China, in which Reviv3 operates, including, without limitation, with respect to taxes, tariffs, trade policies or product safety, which may increase Reviv3's product costs and other costs of doing business, and reduce Reviv3's earnings; and (ix) the impact of unstable market and general economic conditions on Reviv3’s business, financial condition and stock price, including inflationary cost pressures, decreased discretionary consumer spending, supply chain disruptions and constraints, labor shortages, ongoing economic disruption, including the effects of the Ukraine-Russia conflict and ongoing impact of COVID-19, and other downturns in the business cycle or the economy, including any potential recession. There can be no assurance as to any of these matters, and potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. Other important factors that may cause actual results to differ materially from those expressed in the forward-looking statements are discussed in the Company’s filings with the U.S. Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Except as required by law, Reviv3 does not assume any obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
Media Relations:
Reviv3 PR Team
Tel: 888-638-8883
Email: pr@reviv3.com
www.reviv3.com
REVIV3 PROCARE COMPANY AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
| November 30, 2022 | May 31, 2022 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash | $ | 4,018,170 | $ | 373,731 | ||||
| Accounts receivable, net | 791,325 | 105,921 | ||||||
| Inventory, net | 2,113,678 | 323,388 | ||||||
| Prepaid expenses and other current assets | 380,095 | - | ||||||
| Total Current Assets | 7,303,268 | 803,040 | ||||||
| OTHER ASSETS: | ||||||||
| Property and equipment, net | 159,627 | 29,145 | ||||||
| Intangible assets, net | 421,423 | - | ||||||
| Right of use asset | - | 45,453 | ||||||
| Other assets | 20,087 | 16,277 | ||||||
| Goodwill | 2,152,215 | - | ||||||
| Total Other Assets | 2,753,352 | 90,875 | ||||||
| TOTAL ASSETS | $ | 10,056,620 | $ | 893,915 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Accounts payable | $ | 1,322,240 | $ | 435,713 | ||||
| Contract liabilities- current | 817,606 | - | ||||||
| Notes payable | 208,688 | 156,300 | ||||||
| Due to related party | 136,844 | 25,452 | ||||||
| Other current liabilities | 1,450,495 | 89,538 | ||||||
| Total Current Liabilities | 3,935,873 | 707,003 | ||||||
| LONG TERM LIABILITIES: | ||||||||
| Equipment payable | 450 | 2,200 | ||||||
| Contract liabilities- long term | 573,483 | - | ||||||
| Total Long Term Liabilities | 573,933 | 2,200 | ||||||
| Total Liabilities | 4,509,806 | 709,203 | ||||||
| Commitments and contingencies (see Note 10) | - | - | ||||||
| STOCKHOLDERS’ EQUITY: | ||||||||
| Preferred stock, | 25,000 | - | ||||||
| Common stock, | 11,656 | 4,195 | ||||||
| Additional paid-in capital | 9,899,298 | 5,472,084 | ||||||
| Accumulated deficit | (4,389,140 | ) | (5,291,567 | ) | ||||
| Total Stockholders’ Equity | 5,546,814 | 184,712 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 10,056,620 | $ | 893,915 | ||||
REVIV3 PROCARE COMPANY AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND SIX MONTHS ENDED NOVEMBER 30, 2022 AND 2021
(UNAUDITED)
| For the Three Months Ended | For the Six Months Ended | |||||||||||||||
| November 30, | November 30, | November 30, | November 30, | |||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Sales | $ | 6,731,999 | $ | 493,816 | $ | 10,969,357 | $ | 1,333,088 | ||||||||
| Cost of sales | 1,692,965 | 112,800 | 2,647,669 | 476,696 | ||||||||||||
| Gross profit | 5,039,034 | 381,016 | 8,321,688 | 856,392 | ||||||||||||
| OPERATING EXPENSES: | ||||||||||||||||
| Marketing and selling expenses | 3,098,898 | 269,051 | 5,076,874 | 620,673 | ||||||||||||
| Compensation and related taxes | 509,339 | 777 | 790,027 | 11,608 | ||||||||||||
| Professional and consulting expenses | 213,205 | 55,686 | 679,655 | 119,554 | ||||||||||||
| General and administrative | 232,597 | 60,739 | 590,736 | 124,268 | ||||||||||||
| Total Operating Expenses | 4,054,039 | 386,253 | 7,137,292 | 876,103 | ||||||||||||
| INCOME (LOSS) FROM OPERATIONS | 984,995 | (5,237 | ) | 1,184,396 | (19,711 | ) | ||||||||||
| OTHER INCOME (EXPENSE): | ||||||||||||||||
| Gain on debt settlement | - | 35,000 | 50,500 | 35,000 | ||||||||||||
| Interest income | 4,704 | 7 | 6,541 | 18 | ||||||||||||
| Interest expense and other finance charges | (1,755 | ) | (1,569 | ) | (3,213 | ) | (3,145 | ) | ||||||||
| Other Income (Expense), Net | 2,949 | 33,438 | 53,828 | 31,873 | ||||||||||||
| INCOME BEFORE PROVISION FOR INCOME TAXES | 987,944 | 28,201 | 1,238,224 | 12,162 | ||||||||||||
| Provision for income taxes | 261,044 | - | 335,797 | - | ||||||||||||
| NET INCOME | $ | 726,900 | $ | 28,201 | $ | 902,427 | $ | 12,162 | ||||||||
| NET INCOME PER COMMON SHARE: | ||||||||||||||||
| Basic | $ | 0.01 | $ | 0.00 | $ | 0.01 | $ | 0.00 | ||||||||
| Diluted | $ | 0.00 | $ | 0.00 | $ | 0.00 | $ | 0.00 | ||||||||
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: | ||||||||||||||||
| Basic | 115,226,893 | 41,945,881 | 108,779,476 | 41,945,881 | ||||||||||||
| Diluted | 368,933,486 | 41,945,881 | 341,429,203 | 41,945,881 | ||||||||||||
FAQ
What were Reviv3 Procare Company's Q2 2023 revenues?
How much did net income increase for RVIV in Q2 2023?
What factors drove the revenue increase for RVIV in the second quarter of 2023?
What is the future outlook for Reviv3 Procare Company?
